The 5^th Microbiome Movement – Drug Development Summit (October 19-21, Digital Event – EDT) continues to be the industry-leading forum to help forward thinking researchers from the pharmaceutical, biotech and academic community pursue the causal role of the human microbiome in disease, to create a new generation of targeted treatments that demonstrate consistent clinical outcomes and predictable MoAs.

With over 60 speakers taking part, the four focus areas for 2020 include:

• Pre-Clinical Development & Mechanisms of Microbiome-based Therapeutics
  Learn how industry and academic pioneers are developing novel microbiome platforms to identify new targets and therapeutics across a range of microbiome-targeting modalities and disease phenotypes
• Clinical Development, Manufacturing & Commercialization of Live Biotherapeutics
  As the industry prepares for pivotal clinical readouts this summer, this year’s discussion will give you the knowledge and insight required to navigate through the specific translational, clinical and manufacturing challenges for live biotherapeutics
• Microbiome-based Biomarkers, Diagnostics & Patient Stratification
  Mine the human microbiome to discover new biomarkers of disease and help predict response, understand drug metabolism and develop non-invasive diagnostic tools
• Applications in Oncology
  Gain a comprehensive insight into the most exciting disease target in microbiome research today with case-studies and discussion from leading cancer researchers, oncology-specific clinicians and the pharmaceutical industry

If you are, or would like to be, a player in the microbiome arena, this is the conference you should attend to not only hear the latest pre-clinical and clinical development from organizations developing microbiome-based therapeutics, biomarkers and diagnostics, but also to make long-lasting connections that will accelerate your microbiome developments forward, and help translate this promising science into a reality for patients.